CN116249545A - 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化 - Google Patents

在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化 Download PDF

Info

Publication number
CN116249545A
CN116249545A CN202180061630.8A CN202180061630A CN116249545A CN 116249545 A CN116249545 A CN 116249545A CN 202180061630 A CN202180061630 A CN 202180061630A CN 116249545 A CN116249545 A CN 116249545A
Authority
CN
China
Prior art keywords
ifn
copd
treatment
patients
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180061630.8A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·马斯登
菲利普·蒙克
维多利亚·特尔
汤姆·威尔金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synairgen Research Ltd
Original Assignee
Synairgen Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synairgen Research Ltd filed Critical Synairgen Research Ltd
Publication of CN116249545A publication Critical patent/CN116249545A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180061630.8A 2020-09-08 2021-09-07 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化 Pending CN116249545A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2014114.9 2020-09-08
GBGB2014114.9A GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
PCT/GB2021/052302 WO2022053792A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Publications (1)

Publication Number Publication Date
CN116249545A true CN116249545A (zh) 2023-06-09

Family

ID=72841287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180061630.8A Pending CN116249545A (zh) 2020-09-08 2021-09-07 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化

Country Status (7)

Country Link
US (1) US20230241177A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210728A1 (cg-RX-API-DMAC7.html)
JP (1) JP7877300B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066037A (cg-RX-API-DMAC7.html)
CN (1) CN116249545A (cg-RX-API-DMAC7.html)
GB (1) GB202014114D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022053792A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
GB0405634D0 (en) * 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201820659D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy

Also Published As

Publication number Publication date
EP4210728A1 (en) 2023-07-19
US20230241177A1 (en) 2023-08-03
GB202014114D0 (en) 2020-10-21
JP7877300B2 (ja) 2026-06-22
JP2023540591A (ja) 2023-09-25
WO2022053792A1 (en) 2022-03-17
KR20230066037A (ko) 2023-05-12

Similar Documents

Publication Publication Date Title
US6598603B1 (en) Method for treating respiratory diseases
Mainz et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis—results of a multicenter, prospective, randomized, double-blind, controlled trial
US8273342B2 (en) Anti-virus therapy for respiratory diseases
CN104203267A (zh) 用于治疗流感和副流感患者的方法、化合物和组合物
US20220193191A1 (en) Lipocalin mutein for treatment of asthma
EP1922081B1 (en) Interferon lambda therapy for treatment of respiratory diseases
EP3393517B1 (en) Acetylsalicylic acid for use in the treatment of moderate to severe influenza
US20230241177A1 (en) Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
US7871603B2 (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
Abdelfattah et al. Add-on inhalation devices correlation and influence on Asthmatic patients
US11278598B2 (en) Methods for treating diseases associated with respiratory viruses
CN101365474B (zh) 用于治疗呼吸道疾病的干扰素λ疗法
Simões et al. Thermal waters in otorhinolaryngology
WO2022166885A1 (en) Recombinant super-compound interferon (rsifn-co) for treating covid-19 patients with or without symptoms
CA2632032C (en) Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JP2021522263A (ja) 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ
Sirimanne et al. A Randomized Phase 1 Safety Study of Repeated Doses of Intranasal OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adults: A Potential Treatment for Otitis Media
JP2023540591A5 (cg-RX-API-DMAC7.html)
Mason American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019
CN115461356A (zh) 用于预防或治疗covid-19的肽
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
Ferro Treatment of Acute Asthma in the Emergency Setting

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination